{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:10:01Z","timestamp":1756361401333,"version":"3.44.0"},"reference-count":16,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2000,4]]},"abstract":"<jats:p>One of the more disruptive symptoms of eczema is itching. Traditionally, it is treated with emollients, topical corticosteroids or oral antihistamines. A topical form of the antidepressant doxepin (doxepin 5% cream; Xepin - Bioglan) is now marketed for \"the relief of pruritus associated with eczema\" in adults and children aged over 12 years. Here, we review the efficacy and safety of this product and assess its role in the management of eczema.<\/jats:p>","DOI":"10.1136\/dtb.2000.38431","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T16:15:40Z","timestamp":1216397740000},"page":"31-32","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Doxepin cream for eczema?"],"prefix":"10.1136","volume":"38","member":"239","published-online":{"date-parts":[[2000,4,1]]},"reference":[{"key":"2025082722293042000_38.4.31.1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1398-9995.1992.tb05091.x","article-title":"Pathophysiology of itching in urticaria and atopic dermatitis","volume":"47","author":"Wahlgren","year":"1992","journal-title":"Allergy"},{"key":"2025082722293042000_38.4.31.2","first-page":"669","article-title":"Tricyclic antidepressants and histamine H receptors","volume":"54","author":"Richelson","year":"1979","journal-title":"Mayo Clin Proc"},{"key":"2025082722293042000_38.4.31.3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1472-8206.1990.tb00482.x","article-title":"Mechanism of action of doxepin in the treatment of chronic urticaria","volume":"4","author":"Figueiredo","year":"1990","journal-title":"Fundam Clin Pharmacol"},{"key":"2025082722293042000_38.4.31.4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0091-6749(86)90232-0","article-title":"Efficacy of doxepin in the treatment of chronic idiopathic urticaria","volume":"78","author":"Goldsobel","year":"1986","journal-title":"J Allergy Clin Immunol"},{"key":"2025082722293042000_38.4.31.5","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(86)90232-0"},{"key":"2025082722293042000_38.4.31.6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/archderm.1987.01660290115028","article-title":"Antidepressant drugs in dermatology","volume":"113","author":"Gupta","year":"1987","journal-title":"Arch Dermatol"},{"key":"2025082722293042000_38.4.31.7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0190-9622(99)70051-4","article-title":"Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis","volume":"41","author":"Drake","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2025082722293042000_38.4.31.8","unstructured":"Sinequan . Summary of product characteristics, UK. Pfizer Ltd September 1996."},{"key":"2025082722293042000_38.4.31.9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0190-9622(94)70225-X","article-title":"Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream","volume":"31","author":"Drake","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"2025082722293042000_38.4.31.10","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/archderm.1995.01690240065010","article-title":"The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis","volume":"131","author":"Drake","year":"1995","journal-title":"Arch Dermatol"},{"key":"2025082722293042000_38.4.31.11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690240065010"},{"key":"2025082722293042000_38.4.31.12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-0536.1996.tb02374.x","article-title":"Allergic contact dermatitis due to 5% doxepin cream","volume":"35","author":"Bilbao","year":"1996","journal-title":"Contact Dermatitis"},{"key":"2025082722293042000_38.4.31.13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0190-9622(96)90864-6","article-title":"Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream","volume":"34","author":"Shelley","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2025082722293042000_38.4.31.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90864-6"},{"key":"2025082722293042000_38.4.31.15","unstructured":"Xepin . Summary of product characteristics, UK. Bioglan Laboratories Ltd February 1998."},{"key":"2025082722293042000_38.4.31.16","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/archderm.1995.01690240133033","article-title":"Toxic reaction from topically applied doxepin in a child with eczema","volume":"131","author":"Vo","year":"1995","journal-title":"Arch Dermatol"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2000.38431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:29:39Z","timestamp":1756358979000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2000.38431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2000,4,1]]},"published-print":{"date-parts":[[2000,4]]}},"alternative-id":["10.1136\/dtb.2000.38431"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2000.38431","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2000,4]]}}}